

1 **Multiplex Isothermal Amplification Coupled with Nanopore Sequencing for Rapid Detection and**
2 **Mutation Surveillance of SARS-CoV-2**

3
4 **Authors:** Chongwei Bi¹, Gerardo Ramos-Mandujano¹, Sharif Hala^{1, 2, 3}, Jinna Xu¹, Sara Mfarrej¹, Fadwa S.
5 Alofi⁴, Asim Khogeer⁵, Anwar M. Hashem^{6, 7}, Naif A.M. Almontashiri^{8, 9}, Arnab Pain¹, Mo Li^{1,*}

6
7 **Affiliations:**

8 1 Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of
9 Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia

10 2 King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia

11 3 King Abdullah International Medical Research Centre, Jeddah, Makkah, Ministry of National Guard
12 Health Affairs, Jeddah, Makkah, Saudi Arabia

13 4 Infectious Diseases Department, King Fahad Hospital, Madinah, Saudi Arabia

14 5 Plan and Research Department, General Directorate of Health Affairs Makkah Region, MOH, Saudi
15 Arabia

16 6 Vaccines and Immunotherapy Unit, King Fahd Medical Research Center

17 7 King Abdulaziz University, Jeddah, Saudi Arabia

18 8 College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia

19 9 Center for Genetics and Inherited Diseases, Taibah University, Madinah, Saudi Arabia

20 * Correspondence: mo.li@kaust.edu.sa (ML)

21

22

23

24

1 **Abstract**

2
3 Molecular testing and surveillance of the spread and mutation of severe acute respiratory syndrome
4 coronavirus 2 (SARS-CoV-2) are critical public health measures to combat the pandemic. There is an
5 urgent need for methods that can rapidly detect and sequence SARS-CoV-2 simultaneously. Here we
6 describe a method for multiplex isothermal amplification of the SARS-CoV-2 genome in 20 minutes.
7 Based on this, we developed NIRVANA (Nanopore sequencing of Isothermal Rapid Viral Amplification for
8 Near real-time Analysis) to detect viral sequences and monitor mutations in multiple regions of SARS-
9 CoV-2 genome for up to 96 patients at a time. NIRVANA uses a newly developed algorithm for on-the-fly
10 data analysis during Nanopore sequencing. The whole workflow can be completed in as short as 3.5
11 hours, and all reactions can be done in a simple heating block. NIRVANA provides a rapid field-
12 deployable solution of SARS-CoV-2 detection and surveillance of pandemic strains.

13

14 **Main**

15

16 The novel coronavirus disease (COVID-19) pandemic is one of the most serious challenges to public
17 health and global economy in modern history. SARS-CoV-2 is a positive-sense RNA betacoronavirus that
18 causes COVID-19¹. It was identified as the pathogenic cause of an outbreak of viral pneumonia of
19 unknown etiology in Wuhan, China, by the Chinese Center for Disease Control and Prevention (CCDC) on
20 Jan 7, 2020². Three days later, the first SARS-CoV-2 genome was released online through a collaborative
21 effort by scientists in universities in China and Australia and Chinese public health agencies (GenBank:
22 MN908947.3)³. One week after the publication of the genome the first diagnostic detection of SARS-
23 CoV-2 using real-time reverse transcription polymerase chain reaction (rRT-PCR) was released by a
24 group in Germany⁴.

25

26 To date, rRT-PCR assays of various designs, including one approved by the US Centers for Disease
27 Control and Prevention (US CDC) under emergency use authorization (EUA)⁵, have remained the
28 predominant diagnostic method for SARS-CoV-2. Although proven sensitive and specific for providing a
29 positive or negative answer, rRT-PCR provides little information on the genomic sequence of the virus,
30 knowledge of which is crucial for monitoring how SARS-CoV-2 is evolving and spreading and ensuring
31 successful development of new diagnostic tests and vaccines. To this end, samples need to go through a
32 separate workflow—typically Illumina shotgun metagenomics or targeted next-generation sequencing
33 (NGS)⁶. Because NGS requires complicated molecular biology procedures and high-value instruments in
34 centralized laboratories, it is performed in < 1% as many cases as rRT-PCR, evidenced by the number of

1 genomes in the GISAID database (39,954) and confirmed global cases tallied by the WHO (6,535,354) as
2 of June 5, 2020.

3
4 Both rRT-PCR and NGS are sophisticated techniques whose implementation is contingent on the
5 availability of highly-specialized facilities, personnel and reagents. These limitations could translate into
6 long turn-over time or inadequate access to tests even in developed countries. To overcome these
7 issues and accelerate COVID-19 testing, several PCR-free nucleic acid detection assays have been
8 proposed as point-of-care replacements of rRT-PCR. Chief among them is reverse transcription coupled
9 loop-mediated isothermal amplification (RT-LAMP⁷), which has been used for rapid detection of SARS-
10 CoV-2 RNA using colorimetric readout^{8,9}. RT-LAMP can also be coupled to CRISPR-Cas12¹⁰ to increase
11 specificity using lateral flow readout^{11,12}. On the sequencing front, the pocket-sized Oxford Nanopore
12 MinION sequencer has been used for rapid pathogen identification in the field^{13,14}. Because MinION
13 offers base calling on the fly, it is an attractive platform for consolidating viral nucleic acid detection by
14 PCR-free rapid isothermal amplification and viral mutation monitoring by sequencing.

15
16 However, there are several challenges for an integrated point-of-care solution based on RT-LAMP and
17 Nanopore sequencing. RT-LAMP requires a complex mixture of primers that increases the chance of
18 non-specific amplification and makes it difficult to multiplex. Additionally, LAMP amplicons used for
19 SARS-Cov-2 detection are short (<180 bp)^{9,11}. Sequencing singleplex short amplicons not only fails to
20 take advantage of the long-read and sequencing throughput (~10 Gb) of the minION flow cell, it is also
21 prone to false negative reporting due to amplification failure. To the best of our knowledge, no
22 multiplexed isothermal amplification of SARS-CoV-2 has been reported. Nanopore sequencing has its
23 own caveats too. Due to its relatively high basecalling error, sophisticated algorithms are needed for
24 accurate variant detection^{15,16}. New bioinformatics tools are also needed to accurately call the presence of
25 viral sequences (substituting for rRT-PCR) and analyze virus mutations (substituting for NGS).

26
27 Here we developed isothermal recombinase polymerase amplification (RPA) assays to simultaneously
28 amplify multiple regions (up to 1365 bp) of the SARS-CoV-2 genome. This forms the basis for an
29 integrated workflow to detect the presence of viral sequences and monitor mutations in multiple
30 regions of the genome in up to 96 patients at a time (Fig. 1a). We developed a bioinformatics pipeline
31 for on-the-fly analysis to reduce the time to answer and sequencing cost by stopping the sequencing run
32 when data are sufficient to provide confident answers.

1
2 Singleplex RPA was first performed to test its ability to amplify the SARS-CoV-2 genome from a
3 nasopharyngeal swab sample tested positive for the virus using the US CDC assays⁵ (CT value=21).
4 Sixteen primers were tested in 12 combinations to amplify 5 regions harboring either reported signature
5 mutations^{17,18} useful for strain classification or mutation hotspots (GISAID, as of March 15, 2020). Five
6 pairs of primers showed robust amplification of DNA of predicted size (range: 194-466 bp) in a 20-min
7 isothermal reaction at 39 °C (Fig. 1b-c). The specificity of all 5 RPA products was verified by restriction
8 enzyme digestion (Supplementary Fig. 1a). The limit of detection of RPA reaches below 10 copies
9 (Supplementary Fig. 1b). Furthermore, we showed that these RPA reactions could be multiplexed to
10 amplify the five regions of the SARS-CoV-2 genome in a single reaction (Fig. 1d), thus significantly
11 simplifying the workflow.

12
13 We next performed multiplex RPA using ten COVID-19 positive samples (US CDC assays⁵, CT value range:
14 15 to 27.9). Two control samples were also included to test cross-reactivity and specificity. One control
15 sample contained 21 common respiratory pathogens such as influenza virus, coronaviruses (HKU1, 229E,
16 NL63 and OC43), and respiratory syncytial virus, but not SARS-CoV, SARS-CoV-2, or MERSV (see
17 methods), while the other one was a blank control without microorganisms. Multiplex RPA products of
18 the 12 samples were individually barcoded, pooled and prepared into a Nanopore sequencing library
19 using an optimized protocol to save time. The whole workflow from RNA to sequencing takes
20 approximately 4 hours (Fig. 1a).

21
22 The barcoded library was sequenced on a Nanopore MinION using a R9.4.1 flow cell. Besides its
23 excellent portability, the MinION also provides real-time base-calling results. To take advantage of this,
24 we developed a bioinformatics pipeline for real-time analysis of reads, termed Real-Time Nanopore
25 sequencing monitor (RTNano) (Fig. 1e). It continuously monitors the output folder during the
26 sequencing run and generates analysis reports in a matter of seconds. To reduce barcode
27 misclassification during demultiplexing of error-prone Nanopore reads, RTNano included an additional
28 round of demultiplexing using stringent parameters (see methods). After detecting new fastq files,
29 RTNano generated a summary report for each demultiplexed sample, including current read number,
30 base number, and alignment details (Fig. 1e). The alignment statistics were used to determine the
31 presence of the virus. Because base calling and demultiplexing may lead to a brief delay, we refer to the

1 workflow as Nanopore sequencing of Isothermal Rapid Viral Amplification for Near real-time Analysis
2 (NIRVANA) (Fig. 1a).

3
4 In the Nanopore sequencing run of patient samples, RTNano identified the first positive sample at 15
5 minutes, and accurately called all 12 samples at 30 mins (Fig. 2a-b). The 10 positive samples had a deep
6 read coverage of all five amplified regions (Fig. 2a-b, d). We found that the two control samples
7 contained reads mapped to some but not all regions (Fig. 2a-b, d). This could be due to either a small
8 chance of barcode hopping in the one-pot adapter ligation step or fortuitous carryover of positive
9 samples despite our best efforts (see methods). Because of the extraordinary sensitivity of RPA, even a
10 few molecules of viral RNA in aerosols could result in productive amplification. Nonetheless, the lack of
11 any read in 2 out of the 5 target regions even after 12 hours of sequencing clearly distinguish control
12 negative samples from positive ones (Fig. 2c). These data show the importance of using multiple
13 independent RPA amplicons to rule out false positives.

14
15 We acquired a total of 1.7 million reads from this barcoded library (Fig. 2e, Supplementary Fig. 2a). After
16 demultiplexing, the reads were distributed relatively evenly among the barcodes (samples). Due to the
17 stringent demultiplexing procedure, 20.3% of the reads were unclassified. RTNano had an integrated
18 function to quickly analyze variants in each sample during sequencing. It detected 16 single nucleotide
19 variants (SNVs) in the ten positive samples and all of them have been reported in GISAID (Fig. 2f, as of
20 June 7, 2020). The reported SNVs suggested that the strains in samples bc13, bc14, and bc15 are close to
21 clade 19B (nt28144 T/C), first identified in Wuhan, China, while the strains in bc16, and bc19-24 are
22 close to clade 20 (nt14408 C/T, 23403 A/G), first becoming endemic in Europe. Given the fact that bc13,
23 bc14, and bc15 were collected early in the pandemic, while the others were more recent, the SNV
24 signature of the strains revealed by NIRVANA is consistent with the pattern of COVID-19 case
25 importation, which initially came from China and shifted to Europe after a ban of flight from China.
26 Prospectively collecting such data regularly could guide public health policy making to better control the
27 pandemic.

28
29 To validate the SNVs and compare NIRVANA with conventional RT-PCR amplicon sequencing¹⁹, we chose
30 three samples (bc13, bc14 and bc15) to perform multiplex RT-PCR amplicon sequencing on the
31 Nanopore MinION. Variant calling was done by RTNano using the same parameters and the results
32 showed that RT-PCR sequencing confirmed all 3 SNVs detected by NIRVANA (Supplementary Fig. 2b).

1 We further compared the SNVs of bc13, bc14 and bc15 with their corresponding assembled genome
2 from Illumina sequencing published in GISAID (EPI_ISL_437459 for bc13, EPI_ISL_437460 for bc14, and
3 EPI_ISL_437461 for bc15). All of the three SNVs existed in the assembled genome.

4
5 Taken together, NIRVANA provides accurate calling of positive and negative samples on the fly. The
6 whole workflow can be even shorter by performing one-pot RT-RPA (Supplementary Fig. 1c) so that the
7 time from RNA to answer can be as short as 3.5 hours. All molecular biology reactions in the workflow
8 can be done in a simple heating block, and all necessary supplies fit into a briefcase (Fig. 2g,
9 Supplementary Fig. 2c). We expect it to provide a rapid field-deployable solution of pathogen (including
10 but not limited to SARS-CoV-2) detection and surveillance of pandemic strains.

11

12

1 **METHODS**

2

3 *RNA samples and primers*

4

5 Anonymized RNA samples were obtained from Ministry of Health (MOH) hospitals in the western region
6 in Saudi Arabia. The use of clinical samples in this study is approved by the institutional review board
7 (IRB# H-02-K-076-0320-279) of MOH and KAUST Institutional Biosafety and Bioethics Committee (IBEC).
8 Oropharyngeal and nasopharyngeal swabs were carried out by physicians and samples were steeped in
9 1 mL of TRIzol (Invitrogen Cat. No 15596018) to inactivate virus during transportation. Total RNA
10 extraction of the samples was performed following instructions as described in the CDC EUA-approved
11 protocol using the Direct-Zol RNA Miniprep kit (Zymo Research Cat. No R2070) or TRIzol reagent
12 (Invitrogen Cat. No 15596026) following the manufacturers' instructions. The Respiratory (21 targets)
13 control panel (Microbiologics Cat. No 8217) was used as controls in multiplex RPA.

14

15 *Reverse transcription*

16

17 Reverse transcription of RNA samples was done using either NEB ProtoScript II reverse transcriptase
18 (NEB Cat. No M0368) or Invitrogen SuperScript IV reverse transcriptase (Thermo Fisher Scientific Cat. No
19 18090010), following protocols provided by the manufacturers. After reverse transcription, 5 units of
20 thermostable RNase H (New England Biolabs Cat. No M0523S) was added to the reaction, which was
21 incubated at 37 °C for 20 min to remove RNA. The final reaction was diluted 10-fold to be used as
22 templates in RPA. All of the web-lab experiments in this study were conducted in a horizontal flow clean
23 bench to prevent contaminations. The bench was decontaminated with 70% ethanol, DNAZap
24 (Invitrogen, Cat no. AM9890) and RNase AWAY (Invitrogen, Cat no. 10328011) before and after use. The
25 filtered pipette tips (Eppendorf epT.I.P.S.® LoRetention series) and centrifuge tubes (Eppendorf DNA
26 LoBind Tubes, Cat. No 0030108051) used in this study were PCR-clean grade. All of the operations were
27 performed carefully following standard laboratory operating procedures.

28

29 *Singleplex RPA*

30

31 Singleplex RPA was performed using TwistAmp® Basic kit following the standard protocol. Thirteen pairs
32 of primers covering N gene, S gene, ORF1ab and ORF8 were tested and the corresponding amplicons

1 were purified by 0.8X Beckman Coulter AMPure XP beads (Cat. No A63882) and eluted in 40 μ l H₂O. The
2 purified amplicons were first analyzed by running DNA agarose gel to check the specificity and efficiency.
3 The most robust five pairs of primers with correct size were further analyzed by NlaIII (NEB Cat. No
4 R0125L) and SpeI (NEB Cat. No R0133L) digestion following standard protocols. For one-pot RT-RPA, 10
5 U of AMV Reverse Transcriptase (NEB Cat no. M0277S) and 20U of SUPERase•In™ RNase Inhibitor
6 (Invitrogen Cat no. AM2694) were added to a regular RPA reaction mix. The RT-RPA was carried out per
7 the manufacturer protocol.

8

9 *Multiplex RPA*

10

11 Multiplexed RPA was done by add all of the five pairs of primers in the same reaction. The total final
12 primer concentration is limited to 2 μ M. To achieve an even and robust amplification, we empirically
13 determined the final concentration of the primers as follows: 0.166 μ M for each pair-4 primer, 0.166
14 μ M for each pair-5 primer, 0.242 μ M for each pair-9 primer, 0.26 μ M for each pair-10 primer, 0.166 μ M
15 for each pair-13 primer, 29.5 μ l of primer free rehydration buffer, 1 μ l of 10-fold diluted cDNA, 7 μ l H₂O.
16 The reaction was incubated at 39 °C for 4 min, then vortexed and spun down briefly, followed by a 16-
17 min incubation at 39 °C. The RPA reaction was purified using Qiagen QIAquick PCR purification kit
18 (Qiagen Cat No. 28106).

19

20 *Library preparation and sequencing*

21

22 The RPA library preparation was done using Native barcoding expansion kit (Oxford Nanopore
23 Technologies EXP-NBD114) following Nanopore PCR tiling of COVID-19 Virus protocol (Ver:
24 PTC_9096_v109_revE_06Feb2020) with a few changes. We determined the concentration of each RPA
25 samples using a Qubit™ 4 fluorometer with the Qubit™ dsDNA HS Assay Kit (Thermo Fisher Scientific
26 Q32851). The end-prep reaction was done separately in 15 μ l volume using 40 ng of each multiplex RPA
27 samples. After that, we followed the same procedures as described in the official protocol. The RT-PCR
28 library preparation was done using Native barcoding expansion kit (Oxford Nanopore Technologies EXP-
29 NBD104) according to the standard native barcoding amplicons protocol. The sequencing runs were
30 performed on an Oxford Nanopore MinION sequencer using R9.4.1 flow cells.

31

32

1 *Bioinformatics*

2
3 RTNano scanned the sequencing folder repeatedly based on user defined interval time. Once newly
4 generated fastq files were detected, it moved the files to the analysis folder and made a new folder for
5 each sample. If the Nanopore demultiplexing tool guppy is provided, RTNano will do additional
6 demultiplexing to make sure reads are correctly classified. The analysis part utilized minimap2²⁰ to
7 quickly align the reads to the SARS-CoV-2 reference genome (GenBank: NC_045512). After alignment,
8 RTNano will collect key information, including percentage of mapped reads, percentage of mapped
9 bases, percentage of on-target bases, base number that aligned to every targeted region. With the
10 sequencing continuing, RTNano will merge the newly analyzed result with completed ones to update the
11 current sequencing statistics. Users can use these numbers to determine virus-positive samples in real
12 time. A positive sample is characterized by presence of reads covering all of the targeted regions.
13 RTNano is ultra-fast, a typical analysis with additional guppy demultiplexing of 5 fastq files (containing
14 4000 reads each) will take ~10s using one thread in a MacBook Pro 2016 15-inch laptop. Variant calling
15 was performed using samtools (v1.9) and bcftools (v1.9)²¹. The detected variants were filtered by
16 position (within the targeted regions) and compared with the data in Nextstrain.org as of Jun 2, 2020.

17

18 *Data and materials availability*

19

20 RTNano and sequencing data in this study are available upon request.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

REFERENCE:

1 WHO. *Naming the coronavirus disease (COVID-19) and the virus that causes it*,
2 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)
3 [guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)>
4 (2020).

5 2 The nCoV Outbreak Joint Field Epidemiology Investigation Team, Q., Li. An Outbreak of
6 NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province, 2019–2020. *China CDC*
7 *Weekly* **2**, 79-80, doi:10.46234/ccdcw2020.022 (2020).

8 3 Wu, F., Zhao,S., Yu,B., Chen,Y.M., Wang,W., Song,Z.G., Hu,Y., Tao,Z.W., Tian,J.H., Pei,Y.Y.,
9 Yuan,M.L., Zhang,Y.L., Dai,F.H., Liu,Y., Wang,Q.M., Zheng,J.J., Xu,L., Holmes,E.C. and
10 Zhang,Y.Z. Novel 2019 coronavirus genome. (2020).

11 4 Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-
12 PCR. *Euro Surveill* **25**, doi:10.2807/1560-7917.ES.2020.25.3.2000045 (2020).

13 5 Centers for Disease Control and Prevention, R. V. B., Division of Viral Diseases. Real-Time
14 RT-PCR Panel for Detection 2019-Novel Coronavirus. (2020).

15 6 Zhang, Y. Z. & Holmes, E. C. A Genomic Perspective on the Origin and Emergence of
16 SARS-CoV-2. *Cell* **181**, 223-227, doi:10.1016/j.cell.2020.03.035 (2020).

17 7 Notomi, T. *et al.* Loop-mediated isothermal amplification of DNA. *Nucleic acids research*
18 **28**, E63, doi:10.1093/nar/28.12.e63 (2000).

19 8 Zhang, Y. *et al.* Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using
20 Colorimetric LAMP. *medRxiv*, 2020.2002.2026.20028373,
21 doi:10.1101/2020.02.26.20028373 (2020).

22 9 Yan, C. *et al.* Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a
23 reverse transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect*
24 **26**, 773-779, doi:10.1016/j.cmi.2020.04.001 (2020).

25 10 Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O. & Zhang, F. SHERLOCK:
26 nucleic acid detection with CRISPR nucleases. *Nature protocols* **14**, 2986-3012,
27 doi:10.1038/s41596-019-0210-2 (2019).

- 1 11 Broughton, J. P. *et al.* CRISPR-Cas12-based detection of SARS-CoV-2. *Nature*
2 *biotechnology*, doi:10.1038/s41587-020-0513-4 (2020).
- 3 12 Joung, J. *et al.* Point-of-care testing for COVID-19 using SHERLOCK diagnostics. *medRxiv*,
4 2020.2005.2004.20091231, doi:10.1101/2020.05.04.20091231 (2020).
- 5 13 Gardy, J. L. & Loman, N. J. Towards a genomics-informed, real-time, global pathogen
6 surveillance system. *Nature reviews* **19**, 9-20, doi:10.1038/nrg.2017.88 (2018).
- 7 14 Greninger, A. L. *et al.* Rapid metagenomic identification of viral pathogens in clinical
8 samples by real-time nanopore sequencing analysis. *Genome Med* **7**, 99,
9 doi:10.1186/s13073-015-0220-9 (2015).
- 10 15 Bi, C. *et al.* Long-read Individual-molecule Sequencing Reveals CRISPR-induced Genetic
11 Heterogeneity in Human ESCs. *bioRxiv*, 2020.2002.2010.942151,
12 doi:10.1101/2020.02.10.942151 (2020).
- 13 16 Li, Y. *et al.* DeepSimulator1.5: a more powerful, quicker and lighter simulator for
14 Nanopore sequencing. *Bioinformatics* **36**, 2578-2580,
15 doi:10.1093/bioinformatics/btz963 (2020).
- 16 17 Yin, C. Genotyping coronavirus SARS-CoV-2: methods and implications. *Genomics*,
17 doi:10.1016/j.ygeno.2020.04.016 (2020).
- 18 18 Pachetti, M. *et al.* Emerging SARS-CoV-2 mutation hot spots include a novel RNA-
19 dependent-RNA polymerase variant. *J Transl Med* **18**, 179, doi:10.1186/s12967-020-
20 02344-6 (2020).
- 21 19 Team, C.-I. Clinical and virologic characteristics of the first 12 patients with coronavirus
22 disease 2019 (COVID-19) in the United States. *Nature medicine*, doi:10.1038/s41591-
23 020-0877-5 (2020).
- 24 20 Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094-
25 3100, doi:10.1093/bioinformatics/bty191 (2018).
- 26 21 Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,
27 2078-2079, doi:10.1093/bioinformatics/btp352 (2009).

28
29
30

1 **Acknowledgements**

2 We thank KAUST Rapid Research Response Team (R3T) for supporting our research during the COVID-19
3 crisis. We thank members of the KAUST R3T for generously sharing materials and advices. We thank
4 members of the Li laboratory, Yeteng Tian, Baolei Yuan, Xuan Zhou, Yingzi Zhang, and Samhan Alsolami
5 for helpful discussions; Marie Krenz Y. Sicat for administrative support. We thank members of the Pain
6 lab, Rahul Salunke and Amit Subudhi for technical assistance.

8 **Author contributions**

9 ML and CB performed majority of the experiments related to Nanopore sequencing. CB wrote the code
10 and performed the bioinformatics analysis. CB and ML analyzed the data and wrote the manuscript. ML
11 GM and JX performed molecular biology experiments. FSA, AK, AMH, and NAMA collected clinical
12 samples. SM extracted RNA and performed molecular assays. SH and AP coordinated the clinical
13 samples and molecular testing. ML and CB conceived the study. ML supervised the study.

15 **Funding**

16 The research of the Li laboratory was supported by KAUST Office of Sponsored Research (OSR), under
17 award numbers BAS/1/1080-01 and URF/1/3412-01-01, and special support for KAUST R3T from the
18 office of Vice President of Research and OSR.

20 **Figure legend**

22 **Figure 1. Multiplex RPA workflow for SARS-CoV-2 detection and Nanopore sequencing**

23 **a**, Schematic representation of NIRVANA. RNA samples were subjected to reverse transcription,
24 followed by multiplex RPA to amplify multiple regions of the SARS-CoV-2 genome. The amplicons were
25 purified and prepared to the Nanopore library using an optimized barcoding library preparation protocol.
26 In the end, the sequencing was performed in the pocket-sized Nanopore MinION sequencer and
27 sequencing results were analyzed by our algorithm termed RTNano on the fly.

28 **b**, The RPA primers used in this study were plotted in the SARS-CoV-2 genome. The corresponding
29 prevalent variants were labeled under the genome.

30 **c**, Agarose gel electrophoresis results of singleplex RPA with selected primers shown next a molecular
31 size marker. The amplicons range from 194 bp to 466 bp.

1 **d**, Agarose gel electrophoresis results of multiplex RPA. All of the five amplicons were shown in the gel
2 with correct size (asterisks, note that pair 5 and 13 have similar sizes). The no template control (NTC)
3 showed a different pattern of non-specific amplicons. M: molecular size marker.
4 **e**, Pipeline of RTNano real-time analysis. RTNano monitors the Nanopore MinION sequencing output
5 folder. Once newly generated fastq files are detected, it moves the files to the analyzing folder and
6 makes a new folder for each sample. If the Nanopore demultiplexing tool guppy is provided, RTNano will
7 do additional demultiplexing to make sure reads are correctly classified. The analysis will align reads to
8 the SARS-CoV-2 reference genome and collect key information, including percentage of mapped reads,
9 percentage of mapped bases, percentage of on-target bases, base number that aligned to each targeted
10 region. As sequencing proceeds, RTNano will merge the newly analyzed results with existing ones to
11 update the current sequencing statistics.

12

13 **Figure 2. Real-time detection and mutational analysis of COVID-19 samples**

14 **a**, Real-time analysis results by RTNano collected at 15 min after sequencing started. A control sample
15 bc17 was classified as negative because lack of reads in two targeted regions (the last region is a
16 combination of primer pair 4 and 10). Bc18 had not been analyzed at this time. The rest of the samples
17 were classified as positive for SARS-CoV-2.

18 **b**, Real-time analysis results by RTNano collected at 30 min after sequencing started. The other blank
19 control sample bc18 was classified as negative, while classification of the others remained the same.

20 **c**, Similar to (b) but the results were collected after 12 hours of sequencing run. The classification of all
21 samples remained the same.

22 **d**, IGV plots showing Nanopore sequencing read coverage on the SARS-CoV-2 genome. Bc17 and 18
23 showed no read mapped to two targeted regions (red boxes), while other samples showed reads
24 covering all of the targeted regions.

25 **e**, The sequencing throughput of barcoded samples. Twenty percent of reads were binned to
26 unclassified due to the stringent demultiplexing algorithm.

27 **f**, The SNVs detected in multiplex RPA sequencing and their position as shown in the Nextstrain data
28 portal (Nextstrain.org). A total of 16 SNVs were detected from 10 SARS-CoV-2 positive samples.

29 **g**, Equipment used in NIRVANA. The whole workflow can be done with one laptop, one Nanopore
30 MinION sequencer, two pipettes, two boxes of pipette tips, and a heating block (using a miniPCR™
31 mini16 here).

32

1 **Supplementary Figure 1. Agarose gel electrophoresis results of singleplex RPA**

2 a, Agarose gel electrophoresis results of restriction enzyme digestion. The amplicon of pair 5 was
3 digested by SpeI while the others were digested by NlaIII. The digested DNA bands (asterisks) were of
4 expected sizes.

5 b, Agarose gel electrophoresis results showing the sensitivity of RPA in amplifying the SARS-CoV-2
6 genome. Primer pair 4 was used in the experiment. Reliable amplification can be achieved with 1.4
7 copies (calculated from dilution) of the SARS-CoV-2 genome.

8 c, Agarose gel electrophoresis result of one-pot reverse transcription and RPA reaction using primer pair
9 4.

10

11 **Supplementary Figure 2. Alignment of reads on the SARS-CoV-2 genome**



12 a, The length distribution and percent reference identity of all samples sequenced. The unclassified
13 reads were short in size and their overall reference identity was lower than the others.

14 b, IGV plots showing the nt28144 T/C SNV in bc13, 14 and 15 from RPA and RT-PCR Nanopore
15 sequencing. The blue bar represents the C base while the red bar represents the T base. All of the 3
16 SNVs detected in RPA sequencing were confirmed by RT-PCR sequencing.

17 c, Equipment used in the NIRVANA workflow. All equipment can be packed into a suitcase.

18

Fig 1



c medRxiv preprint doi: <https://doi.org/10.1101/2020.06.12.20129247>; this version posted June 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).






Fig 2

a

Real-time report at t=15 min				
position barcode	11050-11244	14307-14500	23123-23431	28086-28752
bc13	83464	51564	7716	419739
bc14	61055	2755	293	131305
bc15	72644	21879	570	230799
bc16	82571	16160	12132	257176
bc17	0	61713	0	58444
bc19	57489	1631	2956	20842
bc20	121330	18593	5535	65892
bc21	109399	32981	50923	177388
bc22	81111	33496	28131	123383
bc23	81326	4440	2037	39093
bc24	64350	38306	47019	166306
unclassified	62259	28187	12237	189886


b

Real-time report at t=30 min				
position barcode	11050-11244	14307-14500	23123-23431	28086-28752
bc13	83464	51564	7716	419739
bc14	61055	2755	293	131305
bc15	72644	21879	570	230799
bc16	82571	16160	12132	257176
bc17	0	61713	0	58444
bc18	77917	0	0	19606
bc19	57489	1631	2956	20842
bc20	121330	18593	5535	65892
bc21	217961	62361	112267	370627
bc22	81111	33496	28131	123383
bc23	81326	4440	2037	39093
bc24	64350	38306	47019	166306
unclassified	62259	28187	12237	189886


c

Real-time report at t=12 h				
position barcode	11050-11244	14307-14500	23123-23431	28086-28752
bc13	1489244	1501820	231185	2457013
bc14	1416000	67056	3593	2402324
bc15	1486060	615167	26348	2341772
bc16	1492765	382994	348951	2181722
bc17	0	1505679	0	1473819
bc18	1489017	0	0	555044
bc19	1488569	90515	68665	643842
bc20	1497581	699870	180039	2295126
bc21	1499434	1310065	2275568	2562861
bc22	1494043	935181	882577	2291800
bc23	1492840	97009	56120	1013864
bc24	1487557	1106883	1423803	2584784
unclassified	1438145	904644	481485	3257502

d




e



f

bc13	28144 T/C
bc14	28144 T/C
bc15	28144 T/C
bc16	14408 C/T
bc19	14408 C/T 23403 A/G 28144 T/C
bc20	14408 C/T 23403 A/G
bc21	14408 C/T 23403 A/G
bc22	14408 C/T 23403 A/G
bc23	23403 A/G
bc24	14408 C/T 23403 A/G




g




Supplementary figure 1

a




medRxiv preprint doi: <https://doi.org/10.1101/2020.06.12.20129247>; this version posted June 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

b



c



Supplementary figure 2

